Sekisui Chemical (4204) · RiskFirst statedLatest Revision of earnings forecasts (2026-07-31): "Mitigated"
Production adjustments for the main products manufactured on a contract basis from pharmaceutical ingredients
First written in FY2025-H1. 1 of 2 entries say "Mitigated", first in 2026-07-31. Latest entry: 2026-07-31.
2entries
3years
1from disclosures
How it moved
Same theme, other companies
Decline in revenue and profit in the pharmaceutical-related businessA theme 5 companies write about · 5 as a headwind · 0 as a tailwind
0 other companies' latest entry also says "Mitigated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- 2026-07-31MitigatedRevision of earnings forecasts
「In the medical business, revenue exceeded the previous year's level due in part to steady shipments of key active pharmaceutical ingredients.」
Shipments of key active pharmaceutical ingredients remained steady, countering the risk of production adjustments for core products described in the previous interim period. - FY2025-H1First statedAnnual report
「医療事業では、医薬品原料の受託製造における主力製品の生産調整の影響があったが」
医薬品原料の受託製造における主力製品の生産調整が、医療事業の業績に実際に影響したと初めて記載された。